MVA EXPRESSING MODIFIED HIV ENVELOPE, GAG AND POL GENES
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
N/A
app pub date -
Dec 10, 2014
filing date -
Mar 8, 2001
priority date (Note) -
Abandoned
status (Latency Note)
![]() |
A preliminary load of PAIR data current through [] has been loaded. Any more recent PAIR data will be loaded within twenty-four hours. |
PAIR data current through []
A preliminary load of cached data will be loaded soon.
Any more recent PAIR data will be loaded within twenty-four hours.
![]() |
Next PAIR Update Scheduled on [ ] |

Importance
Loading Importance Indicators...

Calculated Rating
US Family Size
|
Non-US Coverage
|
Abstract
The invention provides modified virus Ankara (MVA), a replication-deficient strain of vaccinia virus, expressing human immunodeficiency virus (HIV) env, gag, and pol genes.
First Claim
all claims..Other Claims data not available
Family
Loading Family data...

- 15 United States
- 10 France
- 8 Japan
- 7 China
- 5 Korea
- 2 Other
Patent Owner(s)
Patent Owner | Address | |
---|---|---|
EMORY UNIVERSITY | ATLANTA GA |
International Classification(s)

- 2014 Application Filing Year
- A61K Class
- 14144 Applications Filed
- 11600 Patents Issued To-Date
- 82.02 % Issued To-Date
Inventor(s)
Inventor Name | Address | # of filed Patents | Total Citations |
---|---|---|---|
EARL, PATRICIA | Chevy Chase, US | 9 | 47 |
# of filed Patents : 9 Total Citations : 47 | |||
MOSS, BERNARD | Bethesda, US | 51 | 625 |
# of filed Patents : 51 Total Citations : 625 | |||
ROBINSON, HARRIET L | Atlanta, US | 19 | 261 |
# of filed Patents : 19 Total Citations : 261 | |||
WYATT, LINDA | Rockville, US | 8 | 73 |
# of filed Patents : 8 Total Citations : 73 |
Cited Art Landscape
- No Cited Art to Display
Loading Cited Art Landscape... 

Patent Citation Ranking
- 0 Citation Count
- A61K Class
- 0 % this patent is cited more than
- 10 Age
Forward Cite Landscape
- No Forward Cites to Display
Loading Forward Cite Landscape... 

Maintenance Fees
Fee | Large entity fee | small entity fee | micro entity fee | due date |
---|---|---|---|---|
11.5 Year Payment | $7400.00 | $3700.00 | $1850.00 | Feb 27, 2027 |
Fee | Large entity fee | small entity fee | micro entity fee |
---|---|---|---|
Surcharge - 11.5 year - Late payment within 6 months | $160.00 | $80.00 | $40.00 |
Surcharge after expiration - Late payment is unavoidable | $700.00 | $350.00 | $175.00 |
Surcharge after expiration - Late payment is unintentional | $1,640.00 | $820.00 | $410.00 |
Full Text
US Patent Application No: 2013/0281,513
siRNA FOR INHIBITION OF Hif1alpha EXPRESSION AND ANTICANCER COMPOSITION CONTAINING THE SAME
Abstract
Disclosed are small interfering RNA (siRNA) that complementarily binds to a base sequence of Hif1α mRNA transcript, thereby inhibiting expression of Hif1α without inducing immune responses, and a use of the siRNA for prevention and/or treatment of cancer. Since Hif1α is commonly overexpressed in almost all cancer cells, the siRNA that complementarily binds to Hif1α-encoding mRNA may inhibit expression of Hif1α through RNA-mediated interference (RNAi), thereby inhibiting proliferation and metastasis of cancer cells, and thus, the siRNA may be useful as an anticancer agent.
Description
Claims
Claims data not available

Legal Events
- No Legal Status data available.

Matter Detail

Country:
Application No:
Patent No:
Application Publication No:
Status:
Priority Date:
Filing Date:
Matter Type:
Local Registration No:
Docket No:
Secondary System Identifier (SSI):
Customer Application No:
Filing Type:
Request for Examination Date:
Parent Filing Date:
Complete Specification Date:
PCT Filing Date:
National Entry Date:
First Publication Date:
Allowance Date:
Grant Date:
Grant Publication Date:
Claims:
Independent Claims:
Law Firm:
Renewals Detail

Applicant:
Applicant ID:
Entity Size:
Renewal Status:
Renewal Base Date:
Renewal Trigger Date: